Comment
Laura Perrins

The UK’s Transgender Lobby Is Weakened – but Still Advancing

The Cass Review and the Supreme Court restored biological reality to the center of Britain’s transgender debate. Yet the planned puberty-blocker trial shows how far the old consensus still reaches – and how little it takes to silence dissent inside government.

The Cass Review and the UK Supreme Court decision were victories for common sense and child safety, and serious setbacks for the powerful transgender lobby in Britain. They are down, but not out – as the recent demotion of a government minister demonstrates.

One of the recommendations from Cass was that there should be a clinical trial on puberty blockers. The Pathways trial will involve 226 children who believe they are transgender being offered puberty-suppressing drugs, with girls as young as 11 and boys as young as 12 eligible to be medicated in an irreversible way.

This is now subject to legal action and will not commence until 1 August at the earliest. It has received fierce opposition, including from the Conservative Party, which used its opposition day to try to force a vote on the matter. The motion was rejected by 283 to 112. For now, the trial will go ahead. And opposition to it is being swept away.

It was reported last week by The Telegraph that Preet Kaur Gill, a junior health minister in the Labour government, was removed from her position by Health Secretary James Murray after she was “preparing to raise concerns about Pathways with officials at the start of last month”. The newspaper said that “she appears to have been sidelined, and by the time the Medicines and Healthcare products Regulatory Agency announced on 19 June that Pathways could proceed with minimum age limits introduced, responsibility for the trial had passed to Baroness Merron, the minister for women’s health and mental health”.

Welcome to the comments section of the Štandard daily. Please take note of our guidelines, comments are moderated by us. You can contact the moderators at support@statement.com.

Participate in the discussion

Comments are available to subscribers only. If you'd like to join the discussion, choose a subscription starting at €6.72 per month.

All comments 0

    Register

    Comments are available to registered users only. If you'd like to join the discussion, register here.